MA30709B1 - PYRIDO (2, 3-D) PYRIMIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF PI3. - Google Patents
PYRIDO (2, 3-D) PYRIMIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF PI3.Info
- Publication number
- MA30709B1 MA30709B1 MA31707A MA31707A MA30709B1 MA 30709 B1 MA30709 B1 MA 30709B1 MA 31707 A MA31707 A MA 31707A MA 31707 A MA31707 A MA 31707A MA 30709 B1 MA30709 B1 MA 30709B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- pyrido
- pyrimidinone derivatives
- pyrimidinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
CETTE INVENTION CONCERNE DES NOUVEAUX COMPOSÉS DE 4-METHYLPYRIDOPYRIMIDINONE REPRÉSENTÉS PAR LA FORMULE (I), ET DES SELS DE CEUX-CI, LEUR SYNTHÈSE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASE ALPHA (PI3- KA).THIS INVENTION INVOLVES NOVEL 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS REPRESENTED BY FORMULA (I), AND SALTS THEREOF, THEIR SYNTHESIS AND THEIR USE AS INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE ALPHA (PI3-KA).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84506506P | 2006-09-15 | 2006-09-15 | |
US94785207P | 2007-07-03 | 2007-07-03 | |
US95262807P | 2007-07-30 | 2007-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30709B1 true MA30709B1 (en) | 2009-09-01 |
Family
ID=38859750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31707A MA30709B1 (en) | 2006-09-15 | 2009-03-13 | PYRIDO (2, 3-D) PYRIMIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF PI3. |
Country Status (42)
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4718637B2 (en) | 2006-09-15 | 2011-07-06 | ファイザー・プロダクツ・インク | Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors |
EA020022B1 (en) * | 2007-04-10 | 2014-08-29 | Экселиксис, Инк. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
JP2010523681A (en) * | 2007-04-11 | 2010-07-15 | エクセリクシス, インク. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-α for the treatment of cancer |
MX336723B (en) * | 2008-07-11 | 2016-01-28 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway. |
CA2734489C (en) | 2008-08-20 | 2016-11-08 | Southern Research Institute | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
EP2326627A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
AR072940A1 (en) | 2008-08-20 | 2010-09-29 | Schering Corp | PIRIDINE AND PYRIMIDINE DERIVATIVES REPLACED WITH ETHYLLIN AND ITS USE IN THE TREATMENT OF VIRAL INFECTIONS |
US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
US8101622B2 (en) * | 2008-09-30 | 2012-01-24 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
SG190890A1 (en) | 2010-12-16 | 2013-07-31 | Hoffmann La Roche | Tricyclic pi3k inhibitor compounds and methods of use |
US8664230B2 (en) * | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
TW201306842A (en) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab |
WO2013066483A1 (en) | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
CN104829609B (en) * | 2014-02-11 | 2016-08-03 | 北大方正集团有限公司 | Substituted Pyridopyrimidine compound and its preparation method and application |
JP6631616B2 (en) | 2014-07-26 | 2020-01-15 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 2-Amino-pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives as CDK inhibitors and uses thereof |
CN105330699B (en) * | 2014-08-13 | 2018-12-04 | 山东汇睿迪生物技术有限公司 | A kind of phosphorous pyrido [2,3-d] pyrimidin-7-ones class compound or its pharmaceutically acceptable salt, pharmaceutical composition and its application |
KR20170058432A (en) | 2014-10-10 | 2017-05-26 | 화이자 인코포레이티드 | Synergistic auristatin combinations |
SI3302565T1 (en) | 2015-06-04 | 2020-02-28 | Pfizer Inc. | Solid dosage forms of palbociclib |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
EP3481822B1 (en) | 2016-07-06 | 2022-06-22 | The Regents of The University of Michigan | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
EP3497103B1 (en) | 2016-08-15 | 2021-05-05 | Pfizer Inc. | Pyridopyrimdinone cdk2/4/6 inhibitors |
AU2017376766A1 (en) * | 2016-12-14 | 2019-06-06 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
IL279329B1 (en) | 2018-06-15 | 2024-09-01 | Navitor Pharm Inc | Rapamycin analogs and uses thereof |
EP3902801A4 (en) * | 2018-12-28 | 2022-12-14 | SPV Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
US20220220103A1 (en) * | 2018-12-28 | 2022-07-14 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
WO2021139775A1 (en) * | 2020-01-10 | 2021-07-15 | 江苏先声药业有限公司 | Pyridone compound and application |
WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
KR20230121758A (en) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | GCN2 and PERK kinase inhibitors and methods of use thereof |
CA3238551A1 (en) * | 2021-11-18 | 2023-05-25 | Steven FRUCHTMAN | Methods and compositions for treating cancer |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
MD1861G2 (en) | 1994-11-14 | 2002-09-30 | Уорнер-Ламберт Кампэни | Derivatives of the 6-arylpyrido [2,3-d] pyrimidines and naphthyridines, parmaceutical composition on base thereof, methods of treatment and inhibition of the tyrosine kinaze receptor cell proliferation and migration |
CN1177960A (en) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6-substituted pyrazolo (3, 4 -d) pyrimidin -4 ones and compositions and methods of use thereof |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US5925761A (en) | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9904932D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
SK10772002A3 (en) | 2000-01-27 | 2004-01-08 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
AP2002002643A0 (en) | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
ES2360933T3 (en) | 2000-04-27 | 2011-06-10 | Astellas Pharma Inc. | CONDENSED HETEROARILO DERIVATIVES. |
EP1364950A4 (en) | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
JP2003321472A (en) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk inhibitor |
BR0309053A (en) | 2002-04-19 | 2005-02-22 | Smithkline Beecham Corp | Compounds |
KR20050006221A (en) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Nucleoside derivatives for treating hepatitis c virus infection |
JP2004083587A (en) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | Medicinal composition |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
JP2004203751A (en) | 2002-12-24 | 2004-07-22 | Pfizer Inc | Substituted 6,6-heterobicyclic derivative |
US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
WO2004089930A1 (en) | 2003-04-02 | 2004-10-21 | Imclone Systems Incorporated | 4-fluoroquinolone derivatives and their use as kinase inhibitors |
WO2005040337A2 (en) | 2003-05-20 | 2005-05-06 | The Regents Of The University Of California | METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES |
ATE412650T1 (en) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR |
US7326788B2 (en) | 2003-07-22 | 2008-02-05 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
CN1918158B (en) | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | Compounds and compositions as protein kinase inhibitors |
WO2005082903A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
WO2005094830A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
EP1749004B1 (en) * | 2004-05-04 | 2007-09-19 | Warner-Lambert Company LLC | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
EP1761281A1 (en) | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Method for treating abnormal cell growth |
JP2008510770A (en) | 2004-08-26 | 2008-04-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pteridinone as a PLK inhibitor |
WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
CA2590294A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
EP1940839B1 (en) * | 2005-10-07 | 2013-07-31 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha |
AU2006302148B2 (en) * | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
EP1872922A1 (en) * | 2006-06-27 | 2008-01-02 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Method and apparatus for manufacturing a polymeric article |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
JP4718637B2 (en) | 2006-09-15 | 2011-07-06 | ファイザー・プロダクツ・インク | Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors |
BRPI0808772A2 (en) * | 2007-03-14 | 2014-08-12 | Exelixis Inc | HEDGEHOG INHIBITORS |
JP2010523681A (en) | 2007-04-11 | 2010-07-15 | エクセリクシス, インク. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-α for the treatment of cancer |
US8101622B2 (en) | 2008-09-30 | 2012-01-24 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
CN102970868A (en) * | 2010-04-16 | 2013-03-13 | 柯瑞斯公司 | Treatment of cancers having K-RAS mutations |
-
2007
- 2007-09-03 JP JP2009527908A patent/JP4718637B2/en active Active
- 2007-09-03 MX MX2009002927A patent/MX2009002927A/en active IP Right Grant
- 2007-09-03 ES ES07804890T patent/ES2366489T3/en active Active
- 2007-09-03 EP EP07804890.7A patent/EP2074122B9/en active Active
- 2007-09-03 SI SI200730715T patent/SI2074122T1/en unknown
- 2007-09-03 KR KR1020097005342A patent/KR101099926B1/en active IP Right Grant
- 2007-09-03 EA EA200970207A patent/EA016388B1/en not_active IP Right Cessation
- 2007-09-03 ME MEP-80/09A patent/MEP8009A/en unknown
- 2007-09-03 WO PCT/IB2007/002578 patent/WO2008032162A1/en active Application Filing
- 2007-09-03 RS RSP-2009/0104A patent/RS20090104A/en unknown
- 2007-09-03 MY MYPI20091013A patent/MY146420A/en unknown
- 2007-09-03 GE GEAP200711157A patent/GEP20115306B/en unknown
- 2007-09-03 AT AT07804890T patent/ATE514695T1/en active
- 2007-09-03 CN CN2007800342100A patent/CN101573358B/en not_active Expired - Fee Related
- 2007-09-03 DK DK07804890.7T patent/DK2074122T5/en active
- 2007-09-03 BR BRPI0716749A patent/BRPI0716749B8/en not_active IP Right Cessation
- 2007-09-03 NZ NZ575167A patent/NZ575167A/en not_active IP Right Cessation
- 2007-09-03 RS RS20110379A patent/RS51927B/en unknown
- 2007-09-03 CA CA2663401A patent/CA2663401C/en not_active Expired - Fee Related
- 2007-09-03 PT PT07804890T patent/PT2074122E/en unknown
- 2007-09-03 AU AU2007297212A patent/AU2007297212B8/en not_active Ceased
- 2007-09-03 PL PL07804890T patent/PL2074122T3/en unknown
- 2007-09-03 AP AP2009004790A patent/AP2710A/en active
- 2007-09-12 UY UY30588A patent/UY30588A1/en not_active Application Discontinuation
- 2007-09-13 AR ARP070104059A patent/AR062785A1/en not_active Application Discontinuation
- 2007-09-13 PE PE2007001238A patent/PE20080670A1/en not_active Application Discontinuation
- 2007-09-13 GT GT200700077A patent/GT200700077A/en unknown
- 2007-09-13 US US11/854,999 patent/US7696213B2/en not_active Expired - Fee Related
- 2007-09-14 TW TW096134605A patent/TWI334353B/en not_active IP Right Cessation
- 2007-09-14 CL CL200702682A patent/CL2007002682A1/en unknown
- 2007-09-17 HN HN2007000267A patent/HN2007000267A/en unknown
-
2009
- 2009-02-25 IL IL197243A patent/IL197243A/en active IP Right Grant
- 2009-03-02 ZA ZA200901477A patent/ZA200901477B/en unknown
- 2009-03-11 DO DO2009000039A patent/DOP2009000039A/en unknown
- 2009-03-13 CU CU20090040A patent/CU23783B7/en not_active IP Right Cessation
- 2009-03-13 TN TN2009000085A patent/TN2009000085A1/en unknown
- 2009-03-13 MA MA31707A patent/MA30709B1/en unknown
- 2009-03-13 CR CR10662A patent/CR10662A/en unknown
- 2009-03-13 NI NI200900032A patent/NI200900032A/en unknown
- 2009-03-18 NO NO20091141A patent/NO342357B1/en not_active IP Right Cessation
-
2010
- 2010-02-09 US US12/702,937 patent/US8273755B2/en active Active
- 2010-05-03 HK HK10104328.3A patent/HK1138589A1/en not_active IP Right Cessation
-
2011
- 2011-07-20 CY CY20111100714T patent/CY1111911T1/en unknown
- 2011-08-24 HR HRP20110621TT patent/HRP20110621T2/en unknown
-
2012
- 2012-08-16 US US13/587,825 patent/US8633204B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30709B1 (en) | PYRIDO (2, 3-D) PYRIMIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF PI3. | |
MA31574B1 (en) | PYRAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF RAF | |
MA32351B1 (en) | Aminodihydrothiazine derivatives as essential inhibitors for the treatment of Alzheimer's disease | |
MA34644B1 (en) | AMINOPYRIMIDINE PYRAZOLE DERIVATIVES AS MODULATORS OF LRRK2 | |
MA31170B1 (en) | 2-AMINO-5,7-DIHYDRO-6H-PYRROLO [3,4-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF HSP-90 FOR THE TREATMENT OF CANCER | |
EA200970156A1 (en) | PYRDISINOUS DERIVATIVES | |
ATE429427T1 (en) | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | |
ATE542813T1 (en) | 6-SUBSTITUTED 2-HETEROCYCLYLAMINOPYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | |
WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
ATE384061T1 (en) | IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS | |
EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
HRP20090208T1 (en) | Substituted pyrido(2,3-d)pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders | |
MX2009000169A (en) | Purinone derivatives as hm74a agonists. | |
EA201071329A1 (en) | ADAMANTANIA DIAMID DERIVATIVES AND THEIR APPLICATION | |
MA27991A1 (en) | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS LIGANDS OF ADENOSINE A3 | |
MA31080B1 (en) | CYCLED DERIVATIVES AS EG-5 INHIBITORS. | |
DE60214990D1 (en) | BENZOLSULFONIC ACID ESTERS INDOL-5-YL AS 5-HT6 RECEPTOR ANTAGONISTS | |
EA200970936A1 (en) | PYRIDO [2,3-d] PYRIMIDIN-7-IT COMPOUNDS AS PI3K-ALPHA INHIBITORS FOR CANCER TREATMENT | |
TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
MA39707A (en) | 1,2-DIHYDRO-3H-PYRROLO [1,2-C] IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | |
BRPI0509731A (en) | pyrazol [4,3-d] pyrimidines | |
UY32055A (en) | Substituted derivatives of 5-Halo-N2- [substituted] (1-methyl-1H-imidazol-4-yl) pyrimidin-2, -diamine and its pharmaceutically acceptable salts, preparation processes, compositions and applications. | |
EA201170997A1 (en) | INDOL DERIVATIVES AS ANTI-TREATMENT AGENTS | |
MA29943B1 (en) | PYRAZOLO [4,3-D] PYRIMIDINE-5-YLE DERIVATIVES AS PDE5 INHIBITORS | |
MA37719A1 (en) | Pyrimidinone derivatives as anti-malarial agents |